"We are now, within short, ready to initiate the phase 2b study - with the goal of making fostrox + Lenvima the first approved medical treatment for second-line liver cancer" October - DecemberFinanci ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement ...
BioArctic AB's (publ) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as sales of Leqembi reached ?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results